Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, an…
FAIL · Does not pass the screen
4.74 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price4.74 USD at the 6 Nov 2026 close
Fair valueUnder review: its inputs are 12 days old; the analyst targets sit too far from the price to cross-check it.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.14, read 2026-11-01
Ethical does not pass the values gate
Price4.74 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown10.87-56.4% to today ✓Accumulation gives way to Markdown after a 13% slide in 7 weeks
2026-08-14Read Accumulation12.43-61.9% to today Markdown gives way to Accumulation after a 10% rise in 6 weeks
2026-07-02Read Markdown11.35-58.2% to today ✓First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Tonix Pharmaceuticals Holding Corp holds its Markdown at $4.74. Consolidating, no directional conviction, held for 250 days.
As held on the ledger · 2026-11-06
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 250 days
Price at the screen
$4.74
Valuation
N/A trailing · -1.59 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.65
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.47%
Below 33%
Interest-bearing debt is just 0.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
77.18%
Below 49%
Money owed to the company is 77.2% of assets, above the 49% limit.
Fail
Revenue purity
31.63%
Below 5%
31.6% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Tonix Pharmaceuticals's business is fine, but its receivables are about 77% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TNXP's ethical verdict changes
Today TNXP does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Its inputs are 12 days old; the analyst targets sit too far from the price to cross-check it. We show no fair value, margin of safety or value read built on it until the review clears.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TNXP trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markdown$5.11-1.2%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 71%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (4 analysts) rates it strong buy, with a mean price target of $46.
2026-10-29Markdown$5.17-19.2%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 19.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 71%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (4 analysts) rates it strong buy, with a mean price target of $46.
2026-10-22Markdown$6.40-41.1%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 41.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 71%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (4 analysts) rates it strong buy, with a mean price target of $46.
2026-10-02Markdown · changed$10.87-12.6%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 71%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (4 analysts) rates it strong buy, with a mean price target of $46.
2026-09-15Accumulation$12.43+0.0%Entry 5
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 71%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (4 analysts) rates it strong buy, with a mean price target of $46.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 9.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 71%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (4 analysts) rates it strong buy, with a mean price target of $46.
2026-07-18Markdown$11.35+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 71%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (4 analysts) rates it strong buy, with a mean price target of $46.
2026-07-03Markdown$11.35+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markdown$11.35Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.